Clinical Trials · NCT00322348
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 98
- Start date
- Apr 2006
- Locations
- 14 sites, 3 countries
- Primary endpoint
- Percentage of Participants With Progression Free Survival (PFS) at Week 24